Colchicine: Repositioning an “ancient” medicine in the 21st century DOI Creative Commons
Е. Л. Насонов, О. М. Драпкина

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 445 - 464

Published: Oct. 31, 2024

The main indications for colchicine treatment until recently were gout, pericarditis, familial Mediterranean fever and some other auto-inflammatory diseases. expansion of (repositioning) the use in direction prevention cardiovascular complications should be considered as one major events medicine XXI century. Deciphering role inflammation most important mechanism development atherosclerosis has created prerequisites concept anti-inflammatory therapy atherosclerosis, which low-dose can take an place, complementing effects aspirin, statins antihypertensive therapy. analysis materials from randomized placebo-controlled studies indicates a decrease frequency patients with coronary heart disease (by 31%) who have suffered myocardial infarction 23%), well 33%), stroke, need revascularization mortality. low dose (0.5 mg/day) is approved by U.S. Food Drug Administration disease. It assumed that future will place pathology associated atherosclerotic vascular

Language: Английский

Positionspapier zum Post-COVID-Syndrom DOI

Elisabeth Schieffer,

Denise Hilfiker‐Kleiner, Axel Schlitt

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 3, 2025

Citations

0
COVID-19 Infection and Coronary Plaque Progression: An Early Warning of a Potential Public Health Crisis DOI
Jonathan Weir‐McCall, Jack Bell

Radiology, Journal Year: 2025, Volume and Issue: 314(2)

Published: Feb. 1, 2025

HomeRadiologyVol. 314, No. 2 Previous Reviews and CommentaryFree AccessEditorialCOVID-19 Infection Coronary Plaque Progression: An Early Warning of a Potential Public Health CrisisJonathan R. Weir-McCall , Jack S. BellJonathan BellAuthor AffiliationsFrom the Department Cardiovascular Imaging, Biomedical Engineering Imaging Sciences, King's College London, England (J.R.W.M.); Radiology, Royal Brompton Hospital, Guys St. Thomas' NHS Trust, Westminster Bridge Rd, 4th Fl, Lambeth Wing, Office Suite 2, London SE1 7EH, Liverpool Center for Science at University Liverpool, John Moores Heart Chest (J.S.B.).Address correspondence to J.R.W.M. (email: [email protected]).Jonathan BellPublished Online:Feb 4 2025https://doi.org/10.1148/radiol.243767See also article by Dai et al in this issue.MoreSectionsPDF ToolsAdd favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookXLinked In See issue.Jonathan is senior lecturer cardiothoracic radiologist Hospital. His research interests lie use cardiovascular CT better understanding how these can be used improve patient treatment outcomes structural coronary artery disease. He sits on guideline committee SCCT, Certification Accreditation Committee EACVI Diagnostics Advisory NICE.Download as PowerPointJack Bell cardiology registrar National Institute Research academic clinical fellow Centre Science. center around integrating multimodal data, including imaging, risk prediction diseases.Download PowerPoint 5 years since outbreak COVID-19 pandemic, there have been over 750 million documented cases, with 100 United States alone (1). With advent mass vaccinations growing population immunity, morbidity mortality associated acute infection has improved substantially. Resolution does not result cessation consequences COVID-19, however. Long-term sequelae observed across multiple organ systems include 1.6-fold higher events 1 year after (2). The precise mechanisms which influences remain uncertain, although one most compelling hypotheses an interaction between atherosclerosis. Atherosclerosis chronic inflammatory disease, endothelial dysfunction accumulation low-density lipoprotein cholesterol vessel intima leading complex cascade involving both innate adaptive immune system. Both autoimmune conditions (eg, rheumatoid arthritis, bowel psoriasis) viral infections HIV) potentiate relevant pathways, accelerated plaque formation, progression, instability (3,4). evidence less clear infections, studies calcium progression following pneumonia reduced influenza vaccine recipients (5,6). Preclinical shown plausible could influence atherosclerosis, direct effects vascular endothelium platelets via angiotensin-converting enzyme receptor indirect through induction systemic inflammation (7). However, atherosclerosis lacking. angiography (CCTA) ideal tool addressing question. It enables noninvasive quantitative assessment burden atherosclerotic within entire tree. This agree well invasive detect response, predict events. information further complemented pericoronary adipose tissue (PCAT) attenuation, measured same time. elevated PCAT attenuation suggestive inflammation. A recent study 158 patients demonstrated increased prior (8). While useful first glimpse into inflammation, analysis did examine volume, nor it consider consequence elevation attenuation. issue (9) harness serial CCTA scans alongside state-of-the-art image investigate associates outcomes. retrospective single-center analyzed 803 least two examinations performed median interval 3 apart. cohort was stratified according whether confirmed occurred final examination. total 690 2108 plaques had 113 480 not. groups were matched baseline terms traditional factors; medications; C-reactive protein levels; infection; vaccination status; features, volumes, high-risk key finding that exhibited greater annualized percent atheroma volume (mean, 0.90% per ± 0.91 [SD] vs 0.62% 0.68; P < .001) noncalcified 0.78% 0.79 0.42% 0.45; compared without infection. Plaques more likely progress (incidence, 21.0% 15.8%; = .03) exhibit 27.1% 19.8%; At causal mediation analysis—which assumes no unmeasured confounders association exposure, mediators, outcomes—PCAT accounted 10.3% between-group difference progression. Clinical recorded 9 months examination defined lesion level, target failure end point encompassing cardiac death, myocardial infarction, revascularization; major adverse all-cause hospitalization unstable angina. Patients (10.4% 3.1%; adjusted hazard ratio, 2.90; (20.1% 3.8%; 4.8; .002) those should commended their comprehensive large cohort, providing insights potential longer-term COVID-19. Whereas findings certainly suggest strong link infection, always confounding, inherent observational studies. particular, behavior acquiring such mask wearing, status, adherence public health regulations, related reduction behaviors, preventative lifestyle measures medication. similar levels vaccination, before period, medication use, provides some reassurance regard, course guarantee adherence. excluded who required interscan interval, thereby excluding highest risk. Therefore, possible severity consequent Replication multicenter setting, ideally range ethnic backgrounds, validate Asian rates are high. Overall, important hypothesis-generating clinically understudied area. mild raises interesting questions about mechanism. Although shared biologic pathways linking so-called cytokine storm severe COVID-19—namely inflammasome activation downstream interleukin 1β, 6, release—this Indeed, high-sensitivity follow-up normal study. Instead, incidence persistent but localized Mechanisms here antigen persistence, dysregulation, dysfunction, oxidative stress extending postacute phase Causal suggested only responsible overall contribution underestimated because 7 months. If driving force would expect maximal peri-infection period then quiescing. Consistent this, imaged than Further work aid temporal relationship underlying association, determine specific question mechanism essential establishing mitigate guiding we targeting earliest during or long term. From perspective, concerning approach 800 cases worldwide replicated other populations, spectrum severity, becomes best integrate care pathway. Some calculators, QRISK3, already incorporate arthritis lupus erythematosus calculations, reported ratios (10). quantification may help refine risk, given scale numbers infected, integration cost-effective manner challenging. Given magnitude hand, action bring together trials necessary assess strategies, anti-inflammatory medications statins, reduce prevent future events.Disclosures conflicts interest: No relationships. J.S.B. supported fellowship from Hospital Charity.References1. WHO dashboard: cases. World Organization. https://data.who.int/dashboards/covid19/cases. Accessed December 3, 2024. Google Scholar2. Xie Y, Xu E, Bowe B, Al-Aly Z. Nat Med 2022;28(3):583–590. Medline Scholar3. Hemmat N, Ebadi A, Badalzadeh R, Memar MY, Baghi HB. Viral Eur J Clin Microbiol Infect Dis 2018;37(12):2225–2233. Scholar4. Porsch F, Binder CJ. Autoimmune diseases Rev Cardiol 2024;21(11):780–807. Scholar5. Behrouzi Bhatt DL, Cannon CP, al. Association Influenza Vaccination Risk: Meta-analysis. JAMA Netw Open 2022;5(4):e228873. Scholar6. Corrales-Medina VF, Dwivedi G, Taljaard M, pneumonia: MESA PLoS One 2018;13(2):e0191750. Scholar7. Chidambaram V, Kumar Sadaf MI, Initiation Progression Atherosclerosis: Pathophysiology During Beyond Acute Phase. JACC Adv 2024;3(8):101107. Scholar8. Mátyás BB, Benedek I, Blîndu Elevated FAI Index Pericoronary Inflammation Identifies Increased Risk Vulnerability Infection. Int Mol Sci 2023;24(8):7398. Scholar9. Tang X, Hu SARS-CoV-2 Radiology 2025;314(2):e240876. Scholar10. Hippisley-Cox J, Coupland C, Brindle P. Development validation QRISK3 algorithms estimate disease: prospective BMJ 2017;357:j2099. ScholarArticle HistoryReceived: Dec 10 2024Revision requested: 19 received: 2024Accepted: 20 2024Published online: Feb 04 2025 FiguresReferencesRelatedDetailsAccompanying ArticleSARS-CoV-2 Atherosclerotic Angiography Adverse EventsFeb 2025Radiology Vol. Metrics Altmetric Score PDF download

Language: Английский

Citations

0
Variability in Arterial Stiffness and Vascular Endothelial Function After COVID-19 During 1.5 Years of Follow-Up—Systematic Review and Meta-Analysis DOI Creative Commons
Danuta Łoboda, Krzysztof S. Gołba, Piotr Jerzy Gurowiec

et al.

Life, Journal Year: 2025, Volume and Issue: 15(4), P. 520 - 520

Published: March 21, 2025

Increasing long-term observations suggest that coronavirus disease 2019 (COVID-19) vasculopathy may persist even 1.5 years after the acute phase, potentially accelerating development of atherosclerotic cardiovascular diseases. This study systematically reviewed variability brachial flow-mediated dilation (FMD) and carotid-femoral pulse wave velocity (cfPWV) from phase COVID-19 through 16 months follow-up (F/U). Databases including PubMed, Web Science, MEDLINE, Embase were screened for a meta-analysis without language or date restrictions (PROSPERO reference CRD42025642888, last search conducted on 1 February 2025). The quality included studies was assessed using Newcastle–Ottawa Quality Scale. We considered all (interventional pre-post studies, prospective observational randomized, non-randomized trials) FMD cfPWV in adults (aged ≥ 18 years) with laboratory-confirmed compared non-COVID-19 controls changes these parameters during F/U. Twenty-one reported differences FMD, examined between patients control groups various stages: acute/subacute (≤30 days onset), early (>30–90 days), mid-term (>90–180 late (>180–270 very (>270 days) post-COVID-19 recovery. Six while nine did so Data 14 (627 cases 694 controls) 15 (578 703 our meta-analysis. showed significant decrease to (standardized mean difference [SMD]= −2.02, p < 0.001), partial improvements noted recovery (SMD = 0.95, 0.001) 0.92, 0.006). Normalization observed 0.12, 0.69). In contrast, values, which higher than 1.27, remained elevated throughout F/U, no except (SMD= −0.39, 0.001). recovery, values those 0.45, 0.010). manuscript, we discuss how factors, severity COVID-19, persistence syndrome, patient’s initial vascular age, depending metrics age risk influenced time degree improvement.

Language: Английский

Citations

0
Revisiting the Role of Platelet-Activating Factor in COVID-19-Induced Cardiovascular Complications DOI Creative Commons
Smaragdi Antonopoulou

Frontiers in Bioscience-Landmark, Journal Year: 2025, Volume and Issue: 30(3)

Published: March 17, 2025

IMR Press is a leading publisher of open access peer-reviewed biomedical and life sciences journals. We aim to facilitate the dissemination high-quality research in area science. With long tradition wide readership, dedicated making positive contributions academics, corporate libraries as well readers authors. All editors will provide best service for researchers, allowing them have easy smooth publication experience helping maximize impact visibility their research.

Language: Английский

Citations

0
The Involvement and Manifestations of SARS-CoV-2 Virus in Cardiovascular Pathology DOI Creative Commons

Sofia Teodora Hărșan,

Anca Sin

Medicina, Journal Year: 2025, Volume and Issue: 61(5), P. 773 - 773

Published: April 22, 2025

Although the acute phase of COVID-19 pandemic has subsided, emergence post-COVID-19 condition presents a new and complex public health challenge, characterized by persistent, multisystem symptoms that can endure for weeks or months after initial infection with SARS-CoV-2 virus, significantly affecting survivors’ quality life. Among most concerning sequelae are cardiovascular complications, which encompass broad spectrum conditions, including arrhythmias, myocardial damage, postural orthostatic tachycardia syndrome. This narrative review explores burden on reviewing latest relevant findings in literature highlighting different aspects COVID-19’s involvement. investigates pathophysiological mechanisms underlying involvement condition, focus direct viral invasion via ACE2 receptors, immune-mediated injury, cytokine storm, systemic inflammation, endothelial dysfunction, mitochondrial injury. The interplay between pre-existing diseases, such as hypertension, atherosclerosis, diabetes, atrial fibrillation, is also explored, revealing individuals conditions at heightened risk both severe illness long-term complications. Long-term immune activation persistence antigens increasingly recognized contributors to ongoing even mild asymptomatic infections. As healthcare system continues adapt consequences pandemic, deeper understanding these manifestations essential. knowledge will inform development targeted strategies prevention, clinical management, rehabilitation affected patients. Furthermore, insights gained from intersection be instrumental shaping responses future epidemics, necessity multidisciplinary approaches patient care preparedness.

Language: Английский

Citations

0
Proteomic Profiling of Endothelial Cell Secretomes After Exposure to Calciprotein Particles Reveals Downregulation of Basement Membrane Assembly and Increased Release of Soluble CD59 DOI Open Access
Alexander D. Stepanov, Д. К. Шишкова, Victoria Markova

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11382 - 11382

Published: Oct. 23, 2024

Calciprotein particles (CPPs) are essential circulating scavengers of excessive Ca

Language: Английский

Citations

1
Is Platelet-Activating Factor the Missing Link Between COVID-19 and Atherosclerosis? DOI Creative Commons
Constantinos A. Demopoulos, Smaragdi Antonopoulou, Theoharis C. Theoharides

et al.

JACC Advances, Journal Year: 2024, Volume and Issue: 3(12), P. 101397 - 101397

Published: Nov. 9, 2024

Language: Английский

Citations

0
Reply DOI Creative Commons
Vignesh Chidambaram,

Amudha Kumar,

Jawahar L. Mehta

et al.

JACC Advances, Journal Year: 2024, Volume and Issue: 3(12), P. 101396 - 101396

Published: Nov. 11, 2024

Citations

0
Colchicine: Repositioning an “ancient” medicine in the 21st century DOI Creative Commons
Е. Л. Насонов, О. М. Драпкина

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 445 - 464

Published: Oct. 31, 2024

The main indications for colchicine treatment until recently were gout, pericarditis, familial Mediterranean fever and some other auto-inflammatory diseases. expansion of (repositioning) the use in direction prevention cardiovascular complications should be considered as one major events medicine XXI century. Deciphering role inflammation most important mechanism development atherosclerosis has created prerequisites concept anti-inflammatory therapy atherosclerosis, which low-dose can take an place, complementing effects aspirin, statins antihypertensive therapy. analysis materials from randomized placebo-controlled studies indicates a decrease frequency patients with coronary heart disease (by 31%) who have suffered myocardial infarction 23%), well 33%), stroke, need revascularization mortality. low dose (0.5 mg/day) is approved by U.S. Food Drug Administration disease. It assumed that future will place pathology associated atherosclerotic vascular

Language: Английский

Citations

0